Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Dimed S.A. Distribuidora de Medicamentos (PNVL3.SA)
BRL11.09
-0.24 (-2.12%)
BR SAO Healthcare Drug Manufacturers - General
Address
Av Industrial Belgraf, 865 - Industrial
Eldorado do Sul, RS, BR
Eldorado do Sul, RS, BR
CEO
Julio Ricardo Mottin Neto Neto
Website
dimed.com.br
IPO
2000-01-03
ISIN BRPNVLACNOR9
Description
Headquartered in Eldorado do Sul, Brazil, Dimed S.A. Distribuidora de Medicamentos is a Brazilian company that supplies a wide range of goods, including pharmaceuticals, fragrances, personal care products, cosmetics, and dermocosmetics. Its business model encompasses both retail and wholesale operations. The company distributes its merchandise through logistical hubs situated in the states of Rio Grande do Sul, Paraná, and Espírito Santo. Furthermore, it boasts an extensive retail network of 517 stores, located across Rio Grande do Sul, Santa Catarina, Paraná, and São Paulo. Before April 2000, the company was known as Panvel S.A. Drogarias e Farmacias.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
BRL11.09
-0.24 (-2.12%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
829.4K
Beta
0.34
Float Shares
71.74M
Free Float %
48.1%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.25% | +0.93% | -12.31% | -26.54% | +16.67% | -1.73% | +39.02% | +2.23% | -42.48% | +8.18% | +3,148.44% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
11.09
DCF (Unlevered)
46.31
+317.6%
DCF (Levered)
69.84
+529.8%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
80% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 2 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
2.58
Grey zone
Piotroski F-Score
5 / 9
Average
MOAT Score
6 / 10
Developing
Composite Rating
B+
Overall Score
3 / 5
Medium
DCF Score
5 / 5
High
ROE Score
4 / 5
High
ROA Score
4 / 5
High
D/E Score
1 / 5
Low
P/E Score
2 / 5
Medium
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - General: +6.6%+11.5% ★ Q1'26: +15.2% (vs Q1'25)
-
EPS growth Drug Manufacturers - General: +18.2%+18.6% ★ Q1'26: +29.4% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - General: +36.0%+3.6% Q1'26: +1.5% (vs Q1'25)
-
EBIT margin Drug Manufacturers - General: +19.4%+4.3% Q1'26: +4.5% (vs Q1'25)
-
ROIC Drug Manufacturers - General: +10.2%+8.7% Q1'26: +9.7% (vs Q1'25)
-
Share dilution Drug Manufacturers - General: +0.0%-0.1% ★ Q1'26: +0.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - General: -0.29×3.20× Q1'26: 2.74× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 1 EPS Ana. |
Dec 2027 5 Rev. Ana. 1 EPS Ana. |
Dec 2028 4 Rev. Ana. 1 EPS Ana. |
Dec 2029 3 Rev. Ana. |
Dec 2030 3 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2.26B
est: 2.29B (-1.2%)
|
2.43B
est: 2.46B (-1.2%)
|
2.72B
est: 2.74B (-0.7%)
|
2.82B
est: 2.81B (+0.5%)
|
3.23B
est: 3.26B (-0.9%)
|
3.99B
est: 4.04B (-1.2%)
|
4.46B
est: 4.71B (-5.3%)
|
4.94B
est: 5.14B (-3.8%)
|
5.51B
est: 5.60B (-1.6%)
|
6.29B
6.25B – 6.34B
+12.2% YoY
|
7.10B
6.84B – 7.49B
+12.9% YoY
|
8.03B
8.00B – 8.05B
+13.0% YoY
|
9.07B
8.86B – 9.37B
+13.0% YoY
|
10.06B
9.84B – 10.40B
+11.0% YoY
|
| EBITDA |
111.39M
est: 191.02M (-41.7%)
|
132.20M
est: 205.73M (-35.7%)
|
213.27M
est: 229.21M (-7.0%)
|
206.39M
est: 234.39M (-11.9%)
|
278.14M
est: 272.00M (+2.3%)
|
333.02M
est: 337.47M (-1.3%)
|
394.31M
est: 405.85M (-2.8%)
|
427.65M
est: 442.73M (-3.4%)
|
470.83M
est: 482.55M (-2.4%)
|
541.64M
538.39M – 546.49M
+12.2% YoY
|
611.75M
589.31M – 645.54M
+12.9% YoY
|
691.28M
689.22M – 693.34M
+13.0% YoY
|
781.07M
763.56M – 807.39M
+13.0% YoY
|
866.60M
847.17M – 895.81M
+11.0% YoY
|
| EBIT |
87.36M
est: 88.45M (-1.2%)
|
104.07M
est: 95.26M (+9.2%)
|
118.42M
est: 106.14M (+11.6%)
|
88.61M
est: 108.54M (-18.4%)
|
120.36M
est: 125.95M (-4.4%)
|
148.46M
est: 156.27M (-5.0%)
|
194.16M
est: 247.21M (-21.5%)
|
217.44M
est: 269.68M (-19.4%)
|
238.29M
est: 293.93M (-18.9%)
|
329.92M
327.94M – 332.88M
+12.2% YoY
|
372.63M
358.96M – 393.21M
+12.9% YoY
|
421.08M
419.82M – 422.33M
+13.0% YoY
|
475.76M
465.10M – 491.80M
+13.0% YoY
|
527.86M
516.03M – 545.65M
+11.0% YoY
|
| Net Income |
59.80M
est: 59.74M (+0.1%)
|
74.98M
est: 71.91M (+4.3%)
|
76.76M
est: 87.65M (-12.4%)
|
56.15M
est: 66.15M (-15.1%)
|
79.43M
est: 129.29M (-38.6%)
|
86.35M
est: 99.79M (-13.5%)
|
92.91M
est: 91.34M (+1.7%)
|
105.51M
est: 122.58M (-13.9%)
|
124.61M
est: 132.37M (-5.9%)
|
172.67M
170.65M – 183.47M
+30.4% YoY
|
213.38M
205.65M – 221.10M
+23.6% YoY
|
264.00M
247.94M – 266.58M
+23.7% YoY
|
—
— – —
-100.0% YoY
|
—
— – —
|
| SGA |
135.27M
est: 125.43M (+7.8%)
|
141.24M
est: 135.09M (+4.6%)
|
599.85M
est: 150.51M (+298.6%)
|
149.01M
est: 153.91M (-3.2%)
|
179.66M
est: 178.60M (+0.6%)
|
220.14M
est: 221.59M (-0.7%)
|
232.79M
est: 433.50M (-46.3%)
|
288.83M
est: 472.89M (-38.9%)
|
1.31B
est: 515.41M (+155.1%)
|
578.54M
575.06M – 583.71M
+12.2% YoY
|
653.42M
629.46M – 689.51M
+12.9% YoY
|
738.37M
736.17M – 740.57M
+13.0% YoY
|
834.27M
815.57M – 862.39M
+13.0% YoY
|
925.63M
904.88M – 956.83M
+11.0% YoY
|
| EPS |
0.44
est: 0.40 (+10.7%)
|
0.55
est: 0.48 (+15.0%)
|
0.57
est: 0.58 (-2.2%)
|
0.37
est: 0.44 (-15.9%)
|
0.53
est: 0.86 (-38.4%)
|
0.58
est: 0.66 (-12.2%)
|
0.62
est: 0.61 (+0.9%)
|
0.71
est: 0.81 (-12.3%)
|
0.84
est: 0.88 (-4.5%)
|
1.17
1.14 – 1.22
+33.0% YoY
|
1.41
1.37 – 1.47
+20.5% YoY
|
1.70
1.65 – 1.77
+20.6% YoY
|
—
— – —
-100.0% YoY
|
—
— – —
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-27 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-26 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-25 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-22 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-21 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-20 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-19 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-18 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-15 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-14 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-13 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-12 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-11 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-08 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-07 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-06 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-05 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-04 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-30 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-29 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-28 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-27 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-24 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-22 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-20 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
444.01M
OE per share TTM
2.97
Owner's Yield
25.06%
Maintenance CapEx ratio
82.88%
Maint CapEx / Avg PPE
24.5%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 14 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | VanEck Brazil Small-Cap ETF BRF | 0.51% | 116.7K | 0.60% |
| 2 | Sophus Capital Emerging Market Small Cap ETF EMSC | 0.48% | 212.2K | 0.85% |
| 3 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.03% | 200.5K | 0.65% |
| 4 | Avantis Emerging Markets Value ETF AVES | 0.01% | 201.5K | 0.36% |
| 5 | Avantis Emerging Markets ex-China Equity ETF AVXC | 0.01% | 34.1K | 0.33% |
| 6 | Dimensional - Emerging Markets ex China Core Equity ETF DEXC | 0.01% | 18.4K | 0.56% |
| 7 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.00% | 27.3K | 0.44% |
| 8 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 310.6K | 0.39% |
| 9 | Avantis Emerging Markets Equity UCITS ETF USD Acc AVEM.L | 0.00% | 7.8K | 0.35% |
| 10 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 48.7K | 0.46% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
21.5K
Shares Outstanding
149.02M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Antônio Carlos Tocchetto Napp | Chief Financial Officer & Investor Relations Officer | — | male |
| Julio Ricardo Mottin Neto | Chief Executive Officer | — | male |
| Roberto Coimbra Santos | Executive Officer, MD & Director | — | male |
| Sergio Rigon | Controller | — | — |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PNVL3.SA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
